Logo of Mesoblast (ASX:MSB)Latest Mesoblast (ASX:MSB) News

Page 5
Page 5 of 5

Mesoblast’s Ryoncil Launch Marks New Chapter Amid $102M Loss and $161M Cash Buffer

Mesoblast Limited has reported its FY2025 results, highlighting the FDA approval and US commercial launch of Ryoncil, its first mesenchymal stromal cell therapy, alongside a $102.1 million net loss and $161.6 million in cash reserves.
Ada Torres
29 Aug 2025

Mesoblast Prepares to Unveil FY2025 Results Amid Global Expansion

Mesoblast Limited is set to release its full-year financial results and operational highlights for 2025, spotlighting its FDA-approved cell therapy and expanding global partnerships.
Ada Torres
27 Aug 2025

Mesoblast’s Ryoncil Hits US$13.2M in First Quarter Post FDA Launch

Mesoblast has reported a strong commercial debut for Ryoncil, the first FDA-approved mesenchymal stromal cell therapy for pediatric steroid-refractory acute graft-versus-host disease, generating US$13.2 million in gross revenue in its initial quarter. The company is advancing regulatory and clinical milestones while expanding insurance coverage across the US.
Ada Torres
18 July 2025

Mesoblast and FDA Align on Revascor Filing for Ischemic Heart Failure

Mesoblast has secured FDA agreement on key requirements for its Biologics License Application for Revascor, targeting ischemic heart failure patients with reduced ejection fraction. The company aims for accelerated approval by year-end 2025.
Ada Torres
1 July 2025

Mesoblast Advances FDA Approval for Heart Failure and Expands Ryoncil Use

Mesoblast reports positive FDA progress on accelerated approval for Revascor in ischemic heart failure and plans a pivotal trial to extend Ryoncil’s label to adults with graft versus host disease, while its US commercial launch outpaces expectations.
Ada Torres
12 June 2025

Mesoblast Secures 7-Year FDA Orphan-Drug Exclusivity for Ryoncil in Pediatric SR-aGvHD

Mesoblast has been granted a seven-year orphan-drug exclusivity by the FDA for its cell therapy Ryoncil, reinforcing its market position in treating steroid-refractory acute graft versus host disease in children.
Ada Torres
15 May 2025

Mesoblast Launches Ryoncil in US, Bolsters Cash and Clinical Pipeline

Mesoblast has commercially launched Ryoncil in the US for pediatric acute GVHD, backed by a strong cash position and advancing multiple cell therapy programs.
Ada Torres
30 Apr 2025

Mesoblast Advances U.S. Launch of Ryoncil® with $160M Boost and Pipeline Milestones

Mesoblast Limited is set to launch Ryoncil®, the first FDA-approved MSC therapy for pediatric steroid-refractory acute graft-versus-host disease, backed by a recent $160 million financing that strengthens its commercial and clinical development efforts.
Ada Torres
31 Jan 2025

Mesoblast Clinches FDA Nod for Ryoncil®, Raises A$260M to Fuel Growth

Mesoblast has secured FDA approval for Ryoncil®, the first mesenchymal stromal cell therapy for steroid-refractory acute graft versus host disease in children, while raising A$260 million to accelerate clinical trials and commercial rollout.
Ada Torres
31 Jan 2025

Mesoblast Secures A$260M to Propel Ryoncil® US Launch and Clinical Trials

Mesoblast has raised A$260 million through a global private placement to fund the US commercial launch of its FDA-approved cell therapy Ryoncil® and accelerate clinical development in chronic low back pain.
Ada Torres
14 Jan 2025